News Sentiment

ENGN sentiment intelligence

enGene Holdings Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 46 Balanced news tone 70 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.90 Week of 10 Jul 2026
Weighted tone 46/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

74/100 classification confidence.

Company focus 62

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

+6.7% over one week, +17.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

enGene appoints Michael Heffernan as board chairman By Investing.com

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 74/100 classification
One-week reaction 6.7% Price confirming higher
Trend fit Trend inactive 17.3% over four weeks
Fair value -74.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 43
Negative 17

Relevance

Why the article matched

Direct first
Direct company coverage 62
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 7
TradingKey 7
Investing.com 3
simplywall.st 3
Business Wire 2
The Business Journals 2
Investing.com South Africa 2

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 25
Analyst action 8
Regulatory and legal 3
Guidance 2
Deals and strategy 2
Capital return 1
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 70
Intellectia AI Direct company coverage

enGene Therapeutics Inc. Stock Portfolio

This page tracks the simulated stock portfolio for enGene Therapeutics Inc., based on their disclosed 13F filings. As of May 25, 2026, the portfolio has one holding, valued at $2.20 billion, and is entirely focused on the Medical Biology sector. The site provides performance metr

Tone
Positive 61/100
Event
Market update
Published
25 May 2026 20:09
Source
Intellectia AI
Simply Wall Street Direct company coverage

enGene Therapeutics (NasdaqCM:ENGN) Stock Forecast & Analyst Predictions

enGene Therapeutics (ENGN) is forecast to grow earnings by 8.8% and revenue by 64.3% annually, although it is expected to remain unprofitable for the next three years with a negative return on equity. The company recently saw a significant price target decrease by analysts follow

Tone
Negative 34/100
Event
Earnings
Published
15 May 2026 18:09
Source
Simply Wall Street
Stock Titan Direct company coverage

enGene (ENGN) filing: Cormorant and Bihua Chen report 0 shares

Cormorant Asset Management, LP and Bihua Chen have filed an Amendment No. 1 to Schedule 13G/A for enGene Holdings Inc. (ENGN), reporting that they beneficially own 0 shares, which represents 0% of the class. This calculation is based on 66,989,466 shares outstanding as of March 3

Tone
Neutral 50/100
Event
Market update
Published
15 May 2026 17:10
Source
Stock Titan
Stock Titan Direct company coverage

BML Investment Partners reports 9.95% stake in enGene Holdings (ENGN)

BML Investment Partners, L.P. has filed an amended Schedule 13G/A, disclosing a beneficial ownership of 6,669,908 common shares in enGene Holdings Inc. (ENGN), representing 9.95% of the class. The filing indicates shared voting and dispositive power over these shares, with BML Ca

Tone
Neutral 50/100
Event
Deals and strategy
Published
14 May 2026 14:08
Source
Stock Titan
Stock Titan Direct company coverage

BML Investment Partners discloses 7.8% stake in enGene (ENGN) on 05/08/2026

BML Investment Partners, L.P. has reported a beneficial ownership of 5,225,000 common shares, which represents a 7.8% stake in enGene Holdings Inc. (ENGN) as of May 8, 2026. The SEC filing, a Schedule 13G, indicates shared voting and dispositive power over these shares through BM

Tone
Neutral 50/100
Event
Deals and strategy
Published
14 May 2026 01:39
Source
Stock Titan
MarketBeat Direct company coverage

Privium Fund Management B.V. Makes New Investment in enGene Holdings Inc. $ENGN

Privium Fund Management B.V. has reported a new investment in enGene Holdings Inc. (NASDAQ:ENGN), acquiring 352,087 shares valued at approximately $3.18 million in the fourth quarter. This investment constitutes about 0.6% of Privium's portfolio and 0.53% of enGene's outstanding

Tone
Positive 65/100
Event
Earnings
Published
11 May 2026 04:09
Source
MarketBeat
Market source Direct company coverage

enGene Therapeutics (ENGN) Is Down 76.3% After Mixed LEGEND Phase 2 Durability Data Release Has The Bull Case Changed?

enGene Therapeutics (ENGN) recently reported interim Phase 2 LEGEND trial data for its bladder cancer drug candidate, detalimogene voraplasmid. While the data showed a 54% complete response rate, the durability of the response was weaker than expected, leading to a significant 76

Tone
Negative 13/100
Event
Market update
Published
09 May 2026 18:39
Source
Market source
Stock Titan Direct company coverage

ENGN SEC Filings - enGene Therapeutics Inc 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for enGene Therapeutics (ENGN) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event filings (8-K), and insider trading forms (Form 4). It highlights how these filings offer insights into the company's c

Tone
Positive 66/100
Event
Market update
Published
09 May 2026 00:40
Source
Stock Titan
Stock Titan Direct company coverage

[ARS] enGene Therapeutics Inc. SEC Filing

This article reports on an ARS filing by enGene Therapeutics Inc. (ENGN) with the SEC on May 8, 2026, at 04:08 PM. The filing's impact is deemed low, and sentiment neutral. The report also provides an overview of ENGN's stock data, rankings, latest news, and a list of other recen

Tone
Neutral 50/100
Event
Market update
Published
08 May 2026 15:38
Source
Stock Titan
Moomoo Direct company coverage

Guggenheim Downgrades EnGene Holdings to Neutral From Buy

Guggenheim has downgraded EnGene Holdings (NASDAQ: ENGN) from Buy to Neutral. This change reflects the analyst's updated outlook on the company.

Tone
Negative 32/100
Event
Guidance
Published
08 May 2026 13:39
Source
Moomoo
Investing.com South Africa Direct company coverage

Piper Sandler cuts Engene Holdings stock rating on trial concerns By Investing.com

Piper Sandler downgraded Engene Holdings Inc. to Neutral from Overweight and lowered its price target due to concerns about the company's interim clinical data and the competitive profile of its drug, detalimogene. The firm also cited uncertainty regarding the chief medical offic

Tone
Negative 18/100
Event
Analyst action
Published
08 May 2026 13:09
Source
Investing.com South Africa
Moomoo Direct company coverage

Oppenheimer Downgrades EnGene Holdings to Market Perform From Outperform

Oppenheimer has downgraded EnGene Holdings (NASDAQ: ENGN) from an Outperform rating to a Market Perform rating. This change indicates a shift in the analyst's short-term outlook for the company's stock performance.

Tone
Negative 18/100
Event
Analyst action
Published
08 May 2026 12:38
Source
Moomoo
Investing.com UK Direct company coverage

Guggenheim downgrades Engene stock rating on weaker trial data

Guggenheim downgraded Engene Holdings Inc. (NASDAQ:ENGN) to Neutral from Buy after disappointing interim data from its Phase 2 LEGEND study caused the stock to plunge 76%. The firm removed its price target, citing a decline in efficacy compared to a prior analysis, with the drug'

Tone
Negative 14/100
Event
Analyst action
Published
08 May 2026 08:38
Source
Investing.com UK
Investing.com India Direct company coverage

Raymond James downgrades Engene Holdings stock rating on trial results By Investing.com

Raymond James downgraded Engene Holdings Inc. to Outperform from Strong Buy and reduced its price target significantly following disappointing results from the company's LEGEND study. The complete response rate for patients enrolled after October 2025 dropped to 39% from 63%, cau

Tone
Negative 12/100
Event
Analyst action
Published
08 May 2026 08:38
Source
Investing.com India
Investing.com Direct company coverage

Engene stock rating cut to Perform by Oppenheimer on trial data

Oppenheimer downgraded Engene Holdings Inc. (NASDAQ:ENGN) to Perform from Outperform, citing disappointing interim data from the LEGEND trial for bladder cancer and removing its $30 price target. The firm expressed reduced optimism about the drug's competitive position and antici

Tone
Neutral 50/100
Event
Analyst action
Published
08 May 2026 08:09
Source
Investing.com